Ajinomoto Of Japan Buys Rights To P&G Osteo Drug For $210 Million
This article was originally published in PharmAsia News
Executive SummaryJapan's Ajinomoto has agreed to pay $210 million for the rights to an osteoporosis drug from U.S.-based Procter & Gamble. The drug involved is P&G's Actonel (risedronate). With the agreement, Ajinomoto gets to take the drug from the research stage through marketing. While P&G phases out of the pharmaceutical business, Ajinomoto is moving into it, an expansion beyond its basic business of making seasonings. Takeda Pharmaceutical also makes risedronate and markets it in Japan as Benet. (Click here for more
You may also be interested in...
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.